International supply contracts: supplying Peter and snubbing Paul?

12 March 2021
catherine_penny_laura_beagrie_large

Catherine Penny (pictured above, left, with Laura Beagrie), partner, and Laura Beagrie, professional support lawyer, Stevens & Bolton, consider an important issue brought to light by the scramble for coronavirus vaccines.

The recent and very public skirmish between the European Commission and AstraZeneca (LSE: AZN) over the COVID-19 vaccine demonstrates the difficulties suppliers face when demand for their product exceeds supply. This is often a problem for life sciences companies, particularly those supplying drug products, but rarely is the issue debated so openly and hotly. That the competing customers are the recently-divorced UK and European Union (EU) member states has only added salt to the wound.

In brief: AstraZeneca is manufacturing the vital vaccine in the UK and in Europe. It has faced production delays at some European manufacturing sites but not in the UK, leading the Commission to insist that AstraZeneca must use the UK manufactured products to supply under their agreement. However, reportedly, AstraZeneca has said that its UK supply contract prevents this and its contract with the Commission requires it to make 'best reasonable efforts' to supply, which would not extend to breaching its UK supply contract.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical